The global pharmaceutical contract manufacturing and research services market size was exhibited at USD 221.95 billion in 2022 and it is expected to hold around USD 403 billion by 2030, growing at a CAGR of 7.74% from 2022 to 2030.
The global pharmaceutical contract manufacturing and research services market size was exhibited at USD 221.95 billion in 2022 and it is expected to hold around USD 403 billion by 2030, growing at a CAGR of 7.74% from 2022 to 2030.
Pharmaceutical medications are distributed through a process known as pharmaceutical contract manufacturing. Additionally, medicine businesses use production firms to generate their drugs for them. Since they produce a significant amount of goods, working with a manufacturing firm often simplifies their innovations. Manufacturing is also referred to in contracts as the manufacture of items by one company under the label or trademark of another.
Based on their designs and the demands of their clients, contract manufacturers provide services to a range of industries. In contrast, a contract research organization is a business that offers contract manufacturing and research services to the pharmaceutical and medical device industries.
Get the Sample Copy of This Report@ https://www.precedenceresearch.com/sample/2193
Market Growth
The global pharmaceutical contract manufacturing and contract research market is expanding as a result of factors including falling API production costs, increased emphasis on cost-cutting, and rising competitive pressure. Some of the additional drivers boosting the market’s expansion are the companies’ investments in infrastructure, employees, and technology, as well as the rising demand brought on by the ongoing patent cliff for biologic pharmaceuticals.
The pharmaceutical contract manufacturing and contract research market is expanding as a result of some medications’ patents expiring. Even though the branded medication business has experienced considerable income and volume losses due to the generic erosion caused by the patent cliff, patent expiration allows for the emergence of multiple more affordable generic alternatives.
Pharmaceutical Contract Manufacturing and Research Services Market Report Scope
| Report Coverage | Details |
| Market Size In 2022 | USD 221.95 Billion |
| Market Size By 2030 | USD 403 Billion |
| Growth Rate From 2022 to 2030 | CAGR of 7.74% |
| Base Year | 2022 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | By Service, By End-User |
| Companies Mentioned | Thermo Fisher Scientific Inc., Recipharm AB, Piramal Pharma Solutions, Jubilant Pharmova Limited, Curia Global, Inc., Cambrex Corporation, CordenPharma International, Samsung Biologics, FAMAR Health Care Services, WuXiAppTec |
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
Regional Analysis
The market is divided into North America, Europe, Asia Pacific, and the Rest of the World based on the regional analysis. In terms of revenue share in 2016, North America was dominant, but Asia Pacific is anticipated to develop faster than that region. The increase in businesses outsourcing work to this region’s developing economies is contributing to this trend.
The growth of the U.S. healthcare sector has led to a larger share of the North American continent. This share is expected to decline significantly, which will increase the market share of the BRIC nations. However, during the forecast period, Europe is anticipated to grow at the fastest rate. Because of a rapidly ageing population, a growing gap between the supply and demand for pharmaceuticals, the accessibility of a qualified labor pool, and favorable government policies in the region’s developing nations.
Ask Here for Customization@ https://www.precedenceresearch.com/customization/2193
Market Dynamics
Drivers
Due to accelerating technical breakthroughs and escalating globalization, many biotech and pharmaceutical companies are contracting out their research development to these organizations. The global pharmaceutical contract manufacturing and research services market will expand at a faster rate than average during the forecast period as a result of rising investments by large, well-known vendors in a range of clinical and non-clinical research activities outsourced by numerous contract research organizations. These services provide developers with more affordable options for product development.
The decline in the price of producing active pharmaceutical ingredients (API), the increased focus on cost-cutting, and the pressure on prices are other major factors boosting the growth of the global pharmaceutical contract manufacturing and research services market. Staff, technology, infrastructure, and growing demand as a result of the ongoing biologic drug patent cliff are further key drivers influencing the growth of the pharmaceutical contract manufacturing and research services industry.
Restraints
The introduction of COVID-19 caused a temporary halt to the manufacturing and development of ancillary products used in the production of pharmaceuticals, which had an effect on the supply chain and is anticipated to hinder the expansion of the market. The in-house manufacturing pharmaceutical businesses are increasing their investments in their production capacity, though. Due to this, the prospective growth of contract manufacturing services for conventional clients may be constrained, which would hinder industrial growth.
Opportunities
The need for generic drugs is rising, pharmaceutical R&D spending is increasing, and investments in innovative manufacturing technologies are fueling the expansion of the global pharmaceutical contract manufacturing and research services market. The market for pharmaceutical contract manufacturing and research services is predicted to grow in the coming years as a result of factors including the rising demand for biological therapies, a focus on specialty medications, the expansion of the nuclear medicine industry, and developments in cell and gene therapies.
Services Insights
In 2021, the pharmaceutical contract manufacturing and research services market was dominated by the biologics category. During the projection period, the segment’s expansion in the pharmaceutical contract manufacturing and research services market will be significantly fueled by the increased demand for vaccines and biosimilars.
End-User Insights
In 2021, the market for pharmaceutical contract manufacturing and research services was controlled by the large pharmaceutical corporation’s segment. Large pharmaceutical companies’ significant demand for end-to-end services, growing pricing pressure and channel issues in their operations, and the growing need to optimize execution costs as the patents on top-selling medications expire are just a few factors that can contribute to the market’s growth.
Related Reports
Point-of-Care Testing (POCT) Market 2022 To 2030
https://www.precedenceresearch.com/point-of-care-testing-market
Tissue Engineering Market 2022 To 2030
https://www.precedenceresearch.com/tissue-engineering-market
Surgical Tables Market 2022 To 2030
https://www.precedenceresearch.com/surgical-tables-market
Recent Development
- In February 2022, Leading contract development and manufacturing company Recipharm AB (Sweden) announced the purchase of Arranta Bio. The acquisition of Arranta Bio is intended to provide cutting-edge drug developers in the biologics sector with specialized contract development and manufacturing services for medicines used in advanced therapies.
- In June 2020, Moderna, Inc. and Catalent Inc. have joined forces to provide advanced delivery technologies, development, and manufacturing solutions for pharmaceuticals, biologics, cell and gene treatments, and consumer health products. This partnership aims to create a large-scale, commercial fill-finish manufacturing method for Moderna’s COVID-19 vaccine candidate based on mRNA.
- Apr. 2020, ICON PLC, a well-known supplier of services for drug and device research and commercialization to the biotechnology, pharmaceutical, and medical device sectors, announced its partnership with Pfizer Inc. In April 2020, Pfizer Inc. will receive research and commercialization services related to medications and devices under the terms of this agreement.
- In Jul 2021, a strategic cooperation arrangement was inked between Kineta and Samsung BioLogics, a preeminent contract development and manufacturing company. The agreement’s goal is to offer complete CDMO services, including cell line research, clinical drug substance production, and drug product manufacture, in order to assist KVA12.1’s IND submission.
Major Key Players
- Thermo Fisher Scientific Inc.
- Recipharm AB
- Piramal Pharma Solutions
- Jubilant Pharmova Limited
- Curia Global, Inc.
- Cambrex Corporation
- CordenPharma International
- Samsung Biologics
- FAMAR Health Care Services
- WuXiAppTec
Market Segmentation
By Service
- Manufacturing
- API/Bulk Drugs
- Advanced Drug Delivery Formulations Packaging
- Packaging
- Finished Dose Formulations
- Solid Formulations
- Liquid Formulations
- Semi-solid Formulations
- Research
- Oncology
- Vaccines
- Inflammation & Immunology
- Cardiology
- Neuroscience
- Others
By End-User
- Big Pharma
- Small Pharma
- Generic Pharma
- Contract Research Organizations
Regional Segmentation
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
- Latin America (Brazil and Rest of Latin America)
- Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)
https://www.precedenceresearch.com/table-of-content/2193
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Immediate Delivery Available | Buy This Premium Research Report@ https://www.precedenceresearch.com/checkout/2193
You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 9197 992 333